AR033617A1 - Compuestos derivados espirociclicos, metodos para prepararlos y su uso como inhibidores de fosfodiesterasa-7 - Google Patents
Compuestos derivados espirociclicos, metodos para prepararlos y su uso como inhibidores de fosfodiesterasa-7Info
- Publication number
- AR033617A1 AR033617A1 ARP020100993A ARP020100993A AR033617A1 AR 033617 A1 AR033617 A1 AR 033617A1 AR P020100993 A ARP020100993 A AR P020100993A AR P020100993 A ARP020100993 A AR P020100993A AR 033617 A1 AR033617 A1 AR 033617A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- substituted
- heteroatoms
- hydrogen
- optionally interrupted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Compuestos de formulas (1), (2) o (3) donde: a) X1, X2, X3 y X4 son -N, siempre que no más de dos de ellos sean nitrogeno, o -C-R1; R1 es Q1, alquilo, alquenilo o alquinilo inferiores, no sustituidos o sustituidos con uno o varios grupos Q2; X5-R5, X5 es un solo enlace, alquileno, alquenileno o alquinileno inferiores, optativamente interrumpido con 1 o 2 heteroátomos de O, S, S(=O), SO2 o N, los carbonos de estos grupos son no sustituidos o sustituidos con uno o varios grupos, de SR6, OR6, NR6R7, =O, =S, o =N-R6, R6 y R7 son hidrogeno o alquilo inferiores, R5 es arilo, heteroarilo, cicloalquilo optativamente interrumpido con C(=O) o con 1, 2 o 3 heteroátomos de O, S, S(=O), SO2 o N, cicloalquenilo optativamente interrumpido con C(=O) o con 1, 2 o 3 heteroátomos de O, S, S(=O), SO2 o N, o un grupo bicíclico no sustituidos o sustituidos con uno o varios grupos de Q3, heteroarilo o alquilo inferiores optativamente sustituidos con Q3; Q1, Q2 Q3 son hidrogeno, halogeno, CN, NO2, SO3H, P(=O)(OH)2, OR2, OC(=O)R2, C(=O)OR2, SR2, S(=O)R2, C(=O)-NH-SO2-CH3, NR3R4, Q-R2, Q-NR3R4, NR2-Q-NR3R4 o NR3-Q-R2; Q es C(=NR), C(=O), C(=S) o SO2; R es hidrogeno, CN o SO2NH2 o alquilo inferior y R2, R3 y R4 son hidrogeno, alquilo inferior optativamente interrumpido con C(=O), Q4-arilo, Q4-heteroarilo, Q4-cicloalquilo optativamente interrumpido con C(=O) o con 1 o 2 heteroátomos de O, S, S(=O), SO2 o N, o Q4-cicloalquenilo optativamente interrumpido con C(=O) o con 1 o 2 heteroátomos de O, S, S(=O), SO2 o N; Q4 es (CH2)n, alquilo inferior con un heteroátomo de O, S o N, alquenilo o alquinilo inferiores, optativamente sustituidos con alquilo inferior, OR', o NR'R''; R' y R'' son hidrogeno o alquilo inferior; n es un numero entero de 0, 1, 2, 3 o 4; estos grupos son no sustituidos o sustituidos con uno o varios grupos halogeno, CN, CH3, SO3H, SO2CH3, C(=O)-NH-SO2-CH3, CF3, OR6, COOR6, C(=O)R6, NR6R7, NR6C(=O)R7, C(=O)NR6R7 o SO2NR6R7, en donde R6 y R7 son hidrogeno o alquilo inferior optativamente sustituido con uno o dos grupos de OR, COOR, o NRR8; R y R8 son hidrogeno o alquilo inferior y R6 y R7, y/o, R3 y R4, junto con el átomo de nitrogeno al cual están unidos, pueden formar un anillo heterocíclico de 4 a 8 miembros, con uno o dos heteroátomos de O, S, S(=O), SO2 o N, y que puede ser sustituido con (CH2)n-Q5, n es un numero entero de 0, 1, 2 o 3 y Q5 es un anillo heterocíclico de 4 a 8 miembros, con uno o dos heteroátomos de O, S o N y que puede ser sustituido con un alquilo o un alquilo inferior optativamente sustituido con OR', NR'R'', C(=O)NR'R'' o COOR'; R' y R'' son H o alquilo inferior optativamente sustituido con OR o COOR donde R es hidrogeno o alquilo inferior y R' y R'' junto con el átomo de nitrogeno al cual están unidos, pueden formar un anillo heterocíclico de 4 a 8 miembros, con uno o dos heteroátomos seleccionados de O, S o N; o cuando X1 y X2 ambos representan C-R1, los dos sustituyentes R1 pueden formar junto con los átomos de carbono a los cuales están unidos, un anillo heterocíclico de 5 miembros que comprende un átomo de nitrogeno y optativamente un segundo heteroátomo de O, S o N; b) X es O o NR9, donde R9 es hidrogeno, CN, OH, NH2, alquilo, alquenilo o alquinilo inferiores, no sustituidos o sustituidos con cicloalquilo optativamente interrumpido con 1 o 2 heteroátomos de O, S, S(=O), SO2 o N, cicloalquenilo optativamente interrumpido con 1 o 2 heteroátomos elegidos de O, S, S(=O), SO2 o N, arilo, heteroarilo, OR10, COOR10 o NR10R11, donde R10 y R11 son hidrogeno o alquilo inferior; c) Y es O, S o N-R12; R12 es hidrogeno, CN, OH, NH2, alquilo, alquenilo o alquinilo inferiores, no sustituidos o sustituidos con cicloalquilo optativamente interrumpido con 1 o 2 heteroátomos de O, S, S(=O), SO2 o N, cicloalquenilo optativamente interrumpido con 1 o 2 heteroátomos elegidos de O, S, S(=O), SO2 o N, arilo, heteroarilo, OR10, COOR10 o NR10R11, donde R10 y R11 son hidrogeno o alquilo inferior; d) Z es CH-NO2, O, S o NR13, donde R13 es hidrogeno, CN, OH, NH2, arilo, heteroarilo, cicloalquilo optativamente interrumpido con uno o varios heteroátomos de O, S, S(=O), SO2 o N, cicloalquenilo optativamente interrumpido con uno o varios heteroátomos de O, S, S(=O), SO2 o N, C(=O)R14, C(=O)NR14R15, OR14, o alquilo inferior, no sustituido o sustituido con uno o varios grupos que son OR14, COOR10, o NR14R15; R14 y R15 son hidrogeno o alquilo inferior, o, R14 y R15, junto con el átomo de nitrogeno al cual están unidos, pueden formar un anillo heterocíclico de 4 a 8 miembros con uno o dos heteroátomos de O, S o N, sustituido con un alquilo inferior o cuando Y es N-R12 y Z es N-R13, pueden formar juntos grupos -CH=N- o -C=C-, cuando X es N-R9 y Z es N-R13, R9 y R13 pueden formar juntos un grupo -CH=N- o un grupo -C=C-; e) Z1 es H, CH3 o NR16R17, R16 y R17 son hidrogeno, CN, arilo, heteroarilo, cicloalquilo optativamente interrumpido con uno o varios heteroátomos de O, S, S(=O), SO2 o N, cicloalquenilo optativamente interrumpido con uno o varios heteroátomos de O, S, S(=O), SO2 o N, C(=O)R14, C(=O)NR14R15, OR14, o alquilo inferior no sustituido o sustituido con uno o varios grupos de OR14, COOR14 o NR14R15; R14 y R15 son hidrogeno o alquilo inferior y R14 y R15, y/o, R16 y R17, junto con el átomo de nitrogeno al cual están unidos, pueden formar un anillo heterocíclico de 4 a 8 miembros con uno o más heteroátomos de O, S o N, sustituido con un alquilo inferior; f) A es un ciclo elegido del grupo (4), donde A1, A2, A4, A5 y A6 son O, S, C, C(=O), SO, SO2 o N-R18 y R18 es hidrogeno, arilo, heteroarilo, cicloalquilo optativamente interrumpidos con uno o varios heteroátomos de O, S, S(=O), SO2 o N, cicloalquenilo optativamente interrumpido con uno o varios heteroátomos de O, S, S(=O), SO2 o N, alquilo inferior no sustituido o sustituido con arilo, heteroarilo, cicloalquilo optativamente interrumpido con uno o varios heteroátomos de O, S, S(=O), SO2 o N, cicloalquenilo optativamente interrumpido con uno o varios heteroátomos de O, S, S(=O), SO2 o N, CN, NR19R20, C(=O)NR19R20, OR19, C(=O)R19 o C(=O)OR19 en donde R19 y R20 son hidrogeno o alquilo inferior; A3 es O, S, C, C(=O), SO, SO2 o N-R18 cuando A1 y/o A2 son C(=O) o cuando Y es O o S, R18 es lo definido anteriormente; * representa un átomo de carbono que se comparte entre el ciclo A y el ciclo de la cadena principal que contiene X y/o Y; cada carbono del ciclo A es no sustituido o sustituido con 1 o 2 grupos alquilo inferior optativamente sustituido con OR21, NR21R22, COOR21 o CONR21R22, haloalquilo inferior, CN, F, =O, SO2NR19R20, OR19, SR19, C(=O)OR19, C(=O)NR19R20 o NR19R20, donde R19 y R20 son hidrogeno o alquilo inferior optativamente sustituido con OR21, NR21R22, COOR21 o CONR21R22 en donde R21 y R22 son hidrogeno o alquilo inferior, y R19 y R20, y/o, R21 y R22, junto con el átomo de nitrogeno al cual están unidos, pueden formar un anillo heterocíclico de 4 a 8 miembros; 2 átomos del ciclo A, que no son adyacentes, pueden ser unidos por una cadena de 2, 3 o 4 átomos de carbono que puede ser interrumpida con 1 heteroátomo de O, S o N; siempre que no más de dos de los grupos A1, A2, A3, A4, A5 y A6 simultáneamente sean un heteroátomo; el ciclo A no contenga más de 2 carbonos en un estado de hibridacion sp2; cuando X es O, X2 no es C-R1, R1 es un tienilo sustituido con CN o con CN y CH3, un fenilo sustituido con CN, Cl, NO2 o CN y F, Br, F o sus tautomeros, racémicos o isomeros y sus derivados farmacéuticamente aceptables. Se usan en composiciones farmacéuticas como inhibidor de PDE7, para prevencion o tratamiento de enfermedades relacionadas con células T, enfermedades autoinmunes, osteoartritis, esclerosis multiple, enfermedad pulmonar obstructiva cronica, asma, cáncer, síndrome de inmunodeficiencia adquirida, alergia o enfermedad intestinal inflamatoria. Método para preparar los compuestos de formula (1) haciendo reaccionar una urea sustituida con una cetona cíclica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2001/003355 WO2002076953A1 (en) | 2001-03-21 | 2001-03-21 | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
AR033617A1 true AR033617A1 (es) | 2003-12-26 |
Family
ID=8164349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020100993A AR033617A1 (es) | 2001-03-21 | 2002-03-20 | Compuestos derivados espirociclicos, metodos para prepararlos y su uso como inhibidores de fosfodiesterasa-7 |
Country Status (47)
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1400244A1 (en) * | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
GB0230195D0 (en) * | 2002-12-24 | 2003-02-05 | Biofocus Plc | Compound Libraries |
US7723349B2 (en) | 2003-04-24 | 2010-05-25 | Incyte Corporation | Aza spiro alkane derivatives as inhibitors of metalloproteases |
JP2006219374A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pde7阻害作用を有するイミダゾトリアジノン誘導体 |
JP2006219373A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
JP2007501822A (ja) * | 2003-08-12 | 2007-02-01 | エフ.ホフマン−ラ ロシュ アーゲー | コルチコトロピン放出性因子(crf)アンタゴニストとしてのスピロ置換テトラヒドロキナゾリン |
DK1775298T3 (da) | 2004-07-01 | 2013-05-21 | Daiichi Sankyo Co Ltd | Thienopyrazolderivat med PDE7-inhibitorisk aktivitet |
CA2599662A1 (en) * | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of pde7 inhibitors for the treatment of neuropathic pain |
WO2006092692A1 (en) * | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
GB0504209D0 (en) * | 2005-03-01 | 2005-04-06 | Pfizer Ltd | New use of PDE7 inhibitors |
KR100680497B1 (ko) * | 2005-07-25 | 2007-02-08 | 엘지전자 주식회사 | 근거리통신 시스템에서 단말기가 액세스 포인트에 접속하는방법 |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
NZ568694A (en) | 2005-11-09 | 2011-09-30 | Zalicus Inc | Method, compositions, and kits for the treatment of medical conditions |
EA200801145A1 (ru) | 2005-12-02 | 2008-10-30 | Пфайзер Лимитед | Спироциклические производные хиназолина в качестве ингибиторов pde7 |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2026813A2 (en) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US7998971B2 (en) * | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
AU2008230710B2 (en) * | 2007-03-27 | 2014-04-10 | Omeros Corporation | The use of PDE7 inhibitors for the treatment of movement disorders |
WO2008142550A2 (en) * | 2007-05-24 | 2008-11-27 | Pfizer Limited | Spirocyclic derivatives |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
CN103547267A (zh) | 2010-11-08 | 2014-01-29 | 奥默罗斯公司 | 使用pde7抑制剂治疗成瘾和冲动控制障碍 |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
ME03300B (me) | 2012-06-13 | 2019-07-20 | Incyte Holdings Corp | Supsтituisana triciklična jedinjenja као inhibiтori fgfr |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
DK2986610T5 (en) | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
EA038045B1 (ru) | 2015-02-20 | 2021-06-28 | Инсайт Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
KR20180095565A (ko) * | 2015-12-16 | 2018-08-27 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 피리도[1,2-a]피리미돈 유사체, 이의 결정형, 이의 중간체 및 이의 제조방법 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
CN107382976A (zh) * | 2017-07-04 | 2017-11-24 | 孙秀芹 | 一种治疗盆腔炎的化合物及制备方法和应用 |
MX2020000295A (es) * | 2017-07-12 | 2020-07-22 | Dart Neuroscience Llc | Compuestos de benzoxazol y benzofurano sustituidos como inhibidores de pde7. |
EA202092649A1 (ru) | 2018-05-04 | 2021-06-21 | Инсайт Корпорейшн | Соли ингибитора fgfr |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
WO2024038089A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5815979A (ja) | 1981-07-11 | 1983-01-29 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体およびその製造法 |
US4764512A (en) | 1986-08-27 | 1988-08-16 | Rorer Pharmaceutical Corporation | Benzodiazinone-pyridone compounds, cardiotonic compositions including the same, and their uses |
GR1000821B (el) * | 1988-11-22 | 1993-01-25 | Tanabe Seiyaku Co | Μεθοδος παραγωγης παραγωγων κιναζολινονης. |
US5578593A (en) * | 1992-12-11 | 1996-11-26 | Merck & Co., Inc. | Spiro piperidines and homologs promote release of growth hormone |
SK282166B6 (sk) | 1992-12-11 | 2001-11-06 | Merck & Co., Inc. | Spiropiperidínové deriváty, spôsob ich výroby a farmaceutický prostriedok s ich obsahom |
US5602143A (en) * | 1994-12-08 | 1997-02-11 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors |
EE9800116A (et) * | 1995-10-17 | 1998-10-15 | Astra Pharmaceuticals Limited | Farmatseutiliselt aktiivsed kinasoliini ühendid |
CN1205008A (zh) * | 1996-08-30 | 1999-01-13 | 协和发酵工业株式会社 | 咪唑并喹唑啉衍生物 |
US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
WO2000066560A1 (en) * | 1999-05-04 | 2000-11-09 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
US6509334B1 (en) | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
US6358948B1 (en) * | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
JP2002543155A (ja) | 1999-05-04 | 2002-12-17 | ワイス | 抗プロゲスチン及びプロゲスチンを含有する避妊組成物 |
WO2001045707A1 (en) | 1999-12-21 | 2001-06-28 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
-
2001
- 2001-03-21 WO PCT/EP2001/003355 patent/WO2002076953A1/en active Application Filing
- 2001-03-21 AP APAP/P/2003/002857A patent/AP1699A/en active
-
2002
- 2002-03-05 TW TW091104028A patent/TWI267509B/zh not_active IP Right Cessation
- 2002-03-18 RS YUP-740/03A patent/RS50429B/sr unknown
- 2002-03-18 PT PT02732544T patent/PT1373224E/pt unknown
- 2002-03-18 GE GE5294A patent/GEP20053631B/en unknown
- 2002-03-18 NZ NZ527847A patent/NZ527847A/en unknown
- 2002-03-18 CZ CZ20032451A patent/CZ20032451A3/cs unknown
- 2002-03-18 IL IL15765902A patent/IL157659A0/xx active IP Right Grant
- 2002-03-18 PL PL02367058A patent/PL367058A1/xx not_active Application Discontinuation
- 2002-03-18 AT AT02732544T patent/ATE367381T1/de not_active IP Right Cessation
- 2002-03-18 EP EP02732544A patent/EP1373224B1/en not_active Expired - Lifetime
- 2002-03-18 TN TNPCT/EP2002/003594A patent/TNSN03076A1/en unknown
- 2002-03-18 SK SK1156-2003A patent/SK11562003A3/sk not_active Application Discontinuation
- 2002-03-18 CA CA002441313A patent/CA2441313C/en not_active Expired - Fee Related
- 2002-03-18 DK DK02732544T patent/DK1373224T3/da active
- 2002-03-18 EA EA200300906A patent/EA006815B1/ru unknown
- 2002-03-18 OA OA1200300226A patent/OA12454A/en unknown
- 2002-03-18 EE EEP200300459A patent/EE200300459A/xx unknown
- 2002-03-18 UA UA2003098601A patent/UA74243C2/uk unknown
- 2002-03-18 EP EP07104642A patent/EP1801106A3/en not_active Withdrawn
- 2002-03-18 DE DE60221233T patent/DE60221233T2/de not_active Expired - Lifetime
- 2002-03-18 KR KR1020037012247A patent/KR100617435B1/ko not_active IP Right Cessation
- 2002-03-18 WO PCT/EP2002/003594 patent/WO2002074754A1/en active Application Filing
- 2002-03-18 MX MXPA03008485A patent/MXPA03008485A/es active IP Right Grant
- 2002-03-18 ES ES02732544T patent/ES2288552T3/es not_active Expired - Lifetime
- 2002-03-18 JP JP2002573763A patent/JP4086663B2/ja not_active Expired - Fee Related
- 2002-03-18 HU HU0303637A patent/HUP0303637A3/hu unknown
- 2002-03-18 CN CNB028069714A patent/CN100447136C/zh not_active Expired - Fee Related
- 2002-03-18 MY MYPI20020954A patent/MY142045A/en unknown
- 2002-03-18 AU AU2002304800A patent/AU2002304800B2/en not_active Ceased
- 2002-03-18 BR BR0208192-0A patent/BR0208192A/pt not_active IP Right Cessation
- 2002-03-18 SI SI200230587T patent/SI1373224T1/sl unknown
- 2002-03-19 US US10/101,996 patent/US20020198198A1/en not_active Abandoned
- 2002-03-20 SV SV2002000925A patent/SV2003000925A/es not_active Application Discontinuation
- 2002-03-20 AR ARP020100993A patent/AR033617A1/es active IP Right Grant
- 2002-03-20 PA PA20028541601A patent/PA8541601A1/es unknown
- 2002-03-20 GT GT200200053A patent/GT200200053A/es unknown
- 2002-03-20 PE PE2002000212A patent/PE20021010A1/es not_active Application Discontinuation
-
2003
- 2003-08-25 ZA ZA200306601A patent/ZA200306601B/en unknown
- 2003-08-27 EC EC2003004750A patent/ECSP034750A/es unknown
- 2003-08-28 IL IL157659A patent/IL157659A/en not_active IP Right Cessation
- 2003-08-29 IS IS6934A patent/IS2529B/is unknown
- 2003-08-29 CU CU20030188A patent/CU23218A3/es not_active IP Right Cessation
- 2003-09-12 MA MA27310A patent/MA27001A1/fr unknown
- 2003-09-15 HR HR20030740A patent/HRP20030740A2/hr not_active Application Discontinuation
- 2003-09-17 BG BG108181A patent/BG108181A/xx active Pending
- 2003-09-19 NO NO20034187A patent/NO326086B1/no not_active IP Right Cessation
-
2004
- 2004-05-24 US US10/852,404 patent/US7214676B2/en not_active Expired - Fee Related
- 2004-07-06 HK HK04104855.2A patent/HK1061854A1/xx not_active IP Right Cessation
-
2006
- 2006-10-20 US US11/551,687 patent/US20070049558A1/en not_active Abandoned
-
2007
- 2007-08-30 CY CY20071101121T patent/CY1106829T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR033617A1 (es) | Compuestos derivados espirociclicos, metodos para prepararlos y su uso como inhibidores de fosfodiesterasa-7 | |
EA200501617A1 (ru) | Новые гетероциклические соединения, применяемые для лечения нарушений аллергической или воспалительной природы: способы синтеза и содержащие их фармацевтические составы | |
HUP0402065A2 (hu) | Heterobiciklikus szerkezetû hepatitis C vírus polimeráz inhibitorok, eljárás az elõállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0100950A2 (hu) | Ciklusos aminovegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények | |
HUP0303857A2 (hu) | A béta-amiloid-termelés heterociklusos szulfonamid inhibitorai | |
BG106527A (en) | Pharmaceutically active sulfonamide derivatives | |
DE60322267D1 (de) | Chinolinderivate als glucokinase liganden | |
PE20070798A1 (es) | Compuestos heterociclicos como inhibidores de aspartil proteasas | |
AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
CY1108913T1 (el) | Παραγωγα 4 (φαινυλ-πιπεραζινυλ-μεθυλ) βενζαμιδιου και η χρηση τους για τη θεραπευτικη αντιμετωπιση του πονου, του αγχους ή γαστρεντερικων διαταραχων | |
RU2005106353A (ru) | Производные гидантоина и их применение в качестве ингибиторов тасе | |
DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
ATE556058T1 (de) | 1-(2h)-isochinolonderivat | |
HUP0401538A2 (hu) | Új, helyettesített aminometilcsoportot tartalmazó N-(arilszulfonil)-béta-aminosav-származékok, előállításukra alkalmas eljárás és a vegyületeket tartalmazó gyógyászati készítmények | |
AR063804A1 (es) | Compuestos de azoniabiciclo[2.2.2]octano | |
EA200401612A1 (ru) | Противоаллергические средства | |
HRP20041137B1 (hr) | Indolni, azaindolni i srodni heterocikliäśni 4-alkenil piperidinski amidi | |
HUP0301341A2 (hu) | CCR-3 inhibitor hatású piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
NO20053810D0 (no) | Thiofenkarboksamider som inhibitorer av enzymet IKK-2 | |
AR035759A1 (es) | Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos | |
AR064414A1 (es) | Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que | |
AR035235A1 (es) | Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento | |
SE0201937D0 (sv) | Therapeutic agents | |
AR045040A1 (es) | Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos | |
HRP20080243T3 (en) | 4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |